The Income-tax Act, 2025 has introduced a structured compliance and reporting mechanism for companies claiming deductions on in-house research and development (R&D) expenditure. One of the important components of this framework is FORM 12, prescribed under Section 45(2) read with Rule 29 of the Income-tax Rules, 2026.
FORM 12 replaces the earlier reporting structure linked to Form 3CL under the Income-tax Act, 1961, and is designed to strengthen monitoring and verification of tax deductions claimed on approved R&D facilities.
What is FORM 12?
FORM 12 is a statutory report furnished by the prescribed authority in relation to approved in-house R&D facilities. The report is submitted to the jurisdictional Chief Commissioner of Income-tax and plays a critical role in validating deduction claims under Section 45(2).
The form primarily focuses on evaluating the company’s R&D infrastructure, certifying expenditure details, and ensuring that the approved facility complies with the prescribed conditions under the law.
Purpose of FORM 12
According to the FAQs issued, FORM 12 serves multiple objectives, including:
- Examination and evaluation of the in-house R&D facility
- Certification of the facility’s adequacy and recognition status
- Reporting of eligible capital and revenue expenditure
- Enabling tax authorities to verify deductions claimed by companies under Section 45(2)
This reporting mechanism is expected to improve transparency in R&D incentive claims and reduce disputes during assessments.
Who Furnishes FORM 12?
An important clarification provided in the FAQs is that FORM 12 is not filed by the company itself . Instead, it is furnished by the prescribed authority, namely the Secretary of the Department of Scientific and Industrial Research (DSIR) or another authority notified under Rule 29.
The report is submitted directly to the Chief Commissioner of Income-tax, while a copy is also shared with the concerned company for record purposes.
Key Information Covered in FORM 12
The FAQs highlight that FORM 12 includes detailed disclosures such as:
- Particulars of the company and principal officer
- Nature of business and linkage with research objectives
- Details of the in-house R&D facility
- DSIR recognition details
- Confirmation regarding agreement entered under Form 11
- Eligible capital and revenue expenditure
- Information relating to disposal of assets, if applicable
These disclosures form the basis for evaluating the legitimacy and quantum of deductions claimed by the taxpayer company.
Does FORM 12 Guarantee Deduction Approval?
The government has clarified that FORM 12 itself does not determine the final allowability of deduction. It is merely a reporting and certification instrument. The ultimate admissibility of deduction remains subject to verification by the Income-tax Department during assessment or processing of returns.
Further, discrepancies or adverse observations reported in FORM 12 may trigger additional scrutiny and could potentially affect the deduction claimed by the company.
Annual Compliance Requirement
The FAQs also confirm that FORM 12 is required to be furnished periodically for every approved in-house R&D facility, covering expenditure incurred during the relevant tax year.
This makes FORM 12 an essential annual compliance document within the broader R&D tax incentive framework under the new Income-tax regime.
Conclusion
With the introduction of FORM 12, the government appears to be moving towards a more data-driven and accountable framework for granting tax incentives on scientific research and development activities. Companies operating approved R&D facilities should closely monitor the reporting process and ensure proper documentation of eligible expenditure to avoid future disputes.
The FAQs provide much-needed clarity on the scope, filing mechanism, and practical relevance of FORM 12 under the Income-tax Act, 2025.
CAclubindia
